Liabilities and Equity in USD of ELITE PHARMACEUTICALS INC /NV/ from Q1 2011 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly Liabilities and Equity history and change rate from Q1 2011 to Q3 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Liabilities and Equity for the quarter ending 30 Sep 2025 was $117,247,811, a 32.9% increase year-over-year.
Source SEC data
View on sec.gov
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Liabilities and Equity (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $117,247,811 +$29,049,815 +32.9% 30 Sep 2025 10-Q 14 Nov 2025 2026 Q2
Q2 2025 $111,339,370 +$23,493,365 +26.7% 30 Jun 2025 10-Q 14 Aug 2025 2026 Q1
Q1 2025 $96,387,477 +$12,733,941 +15.2% 31 Mar 2025 10-Q 14 Nov 2025 2026 Q2
Q4 2024 $90,756,464 +$16,060,185 +21.5% 31 Dec 2024 10-Q 13 Feb 2025 2025 Q3
Q3 2024 $88,197,996 +$17,479,043 +24.7% 30 Sep 2024 10-Q 14 Nov 2024 2025 Q2
Q2 2024 $87,846,005 +$41,346,508 +88.9% 30 Jun 2024 10-Q 14 Aug 2024 2025 Q1
Q1 2024 $83,653,536 +$42,757,518 +105% 31 Mar 2024 10-K 30 Jun 2025 2025 FY
Q4 2023 $74,696,279 +$21,980,145 +41.7% 31 Dec 2023 10-Q 14 Feb 2024 2024 Q3
Q3 2023 $70,718,953 +$20,375,703 +40.5% 30 Sep 2023 10-Q 14 Nov 2023 2024 Q2
Q2 2023 $46,499,497 -$1,608,751 -3.34% 30 Jun 2023 10-Q 14 Aug 2023 2024 Q1
Q1 2023 $40,896,018 +$5,747,120 +16.4% 31 Mar 2023 10-K 01 Jul 2024 2024 FY
Q4 2022 $52,716,134 +$20,769,238 +65% 31 Dec 2022 10-Q 14 Feb 2023 2023 Q3
Q3 2022 $50,343,250 +$19,718,823 +64.4% 30 Sep 2022 10-Q 14 Nov 2022 2023 Q2
Q2 2022 $48,108,248 +$18,115,531 +60.4% 30 Jun 2022 10-Q 15 Aug 2022 2023 Q1
Q1 2022 $35,148,898 +$8,959,406 +34.2% 31 Mar 2022 10-K 29 Jun 2023 2023 FY
Q4 2021 $31,946,896 +$3,281,659 +11.4% 31 Dec 2021 10-Q 14 Feb 2022 2022 Q3
Q3 2021 $30,624,427 +$3,018,509 +10.9% 30 Sep 2021 10-Q 15 Nov 2021 2022 Q2
Q2 2021 $29,992,717 +$2,170,984 +7.8% 30 Jun 2021 10-Q 16 Aug 2021 2022 Q1
Q1 2021 $26,189,492 +$1,232,912 +4.94% 31 Mar 2021 10-K 29 Jun 2022 2022 FY
Q4 2020 $28,665,237 +$4,578,727 +19% 31 Dec 2020 10-Q 16 Feb 2021 2021 Q3
Q3 2020 $27,605,918 +$4,072,451 +17.3% 30 Sep 2020 10-Q 16 Nov 2020 2021 Q2
Q2 2020 $27,821,733 +$3,536,780 +14.6% 30 Jun 2020 10-Q 14 Aug 2020 2021 Q1
Q1 2020 $24,956,580 +$554,646 +2.27% 31 Mar 2020 10-K 14 Jun 2021 2021 FY
Q4 2019 $24,086,510 -$2,290,854 -8.68% 31 Dec 2019 10-Q 10 Feb 2020 2020 Q3
Q3 2019 $23,533,467 -$3,787,634 -13.9% 30 Sep 2019 10-Q 12 Nov 2019 2020 Q2
Q2 2019 $24,284,953 -$4,210,299 -14.8% 30 Jun 2019 10-Q 09 Aug 2019 2020 Q1
Q1 2019 $24,401,934 -$6,480,674 -21% 31 Mar 2019 10-K 29 Jun 2020 2020 FY
Q4 2018 $26,377,364 -$5,696,796 -17.8% 31 Dec 2018 10-Q 11 Feb 2019 2019 Q3
Q3 2018 $27,321,101 -$4,691,491 -14.7% 30 Sep 2018 10-Q 09 Nov 2018 2019 Q2
Q2 2018 $28,495,252 -$5,392,376 -15.9% 30 Jun 2018 10-Q 09 Aug 2018 2019 Q1
Q1 2018 $30,882,608 -$3,428,534 -9.99% 31 Mar 2018 10-K 21 Jun 2019 2019 FY
Q4 2017 $32,074,160 -$4,125,509 -11.4% 31 Dec 2017 10-Q 09 Feb 2018 2018 Q3
Q3 2017 $32,012,592 -$2,857,254 -8.19% 30 Sep 2017 10-Q 09 Nov 2017 2018 Q2
Q2 2017 $33,887,628 +$828,557 +2.51% 30 Jun 2017 10-Q 09 Aug 2017 2018 Q1
Q1 2017 $34,311,142 +$2,636,993 +8.32% 31 Mar 2017 10-K 14 Jun 2018 2018 FY
Q4 2016 $36,199,669 +$9,068,796 +33.4% 31 Dec 2016 10-Q 09 Feb 2017 2017 Q3
Q3 2016 $34,869,846 +$6,171,102 +21.5% 30 Sep 2016 10-Q 09 Nov 2016 2017 Q2
Q2 2016 $33,059,071 +$3,147,018 +10.5% 30 Jun 2016 10-Q 09 Aug 2016 2017 Q1
Q1 2016 $31,674,149 +$5,753,870 +22.2% 31 Mar 2016 10-K 14 Jun 2017 2017 FY
Q4 2015 $27,130,873 +$1,429,622 +5.56% 31 Dec 2015 10-Q 09 Feb 2016 2016 Q3
Q3 2015 $28,698,744 +$4,809,585 +20.1% 30 Sep 2015 10-Q 30 Dec 2015 2016 Q2
Q2 2015 $29,912,053 +$5,943,762 +24.8% 30 Jun 2015 10-Q 30 Dec 2015 2016 Q1
Q1 2015 $25,920,279 +$1,602,557 +6.59% 31 Mar 2015 10-K 15 Jun 2016 2016 FY
Q4 2014 $25,701,251 +$7,424,528 +40.6% 31 Dec 2014 10-Q 17 Feb 2015 2015 Q3
Q3 2014 $23,889,159 +$6,477,252 +37.2% 30 Sep 2014 10-Q 14 Nov 2014 2015 Q2
Q2 2014 $23,968,291 +$13,576,172 +131% 30 Jun 2014 10-Q 14 Aug 2014 2015 Q1
Q1 2014 $24,317,722 +$13,192,589 +119% 31 Mar 2014 10-K 15 Jun 2015 2015 FY
Q4 2013 $18,276,723 +$7,905,585 +76.2% 31 Dec 2013 10-Q 14 Feb 2014 2013 Q3
Q3 2013 $17,411,907 +$7,338,042 +72.8% 30 Sep 2013 10-Q 14 Nov 2013 2013 Q2
Q2 2013 $10,392,119 +$205,012 +2.01% 30 Jun 2013 10-Q 14 Aug 2013 2013 Q1
Q1 2013 $11,125,133 +$813,416 +7.89% 31 Mar 2013 10-K 30 Jun 2014 2014 FY
Q4 2012 $10,371,138 +$21,935 +0.21% 31 Dec 2012 10-Q 14 Feb 2013 2012 Q3
Q3 2012 $10,073,865 -$760,824 -7.02% 30 Sep 2012 10-Q 14 Nov 2012 2012 Q2
Q2 2012 $10,187,107 -$1,303,122 -11.3% 30 Jun 2012 10-Q 14 Aug 2012 2012 Q1
Q1 2012 $10,311,717 -$1,476,145 -12.5% 31 Mar 2012 10-K 21 Jun 2013 2012 FY
Q4 2011 $10,349,203 31 Dec 2011 10-Q 14 Feb 2012 2011 Q3
Q3 2011 $10,834,689 30 Sep 2011 10-Q 14 Nov 2011 2011 Q2
Q2 2011 $11,490,229 30 Jun 2011 10-Q/A 19 Aug 2011 2011 Q1
Q1 2011 $11,787,862 31 Mar 2011 10-K 29 Jun 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.